World Health Organization advised against treating hospitalized coronavirus patients with Gilead Sciences Inc.’s Remdesivir, weeks after U.S.
regulators granted the drug a speedy approval.The recommendation is a blow to the drug, one of the first thought to offer a meaningful benefit in treatment of coronavirus patients after a study showed it reduced their recovery time.